Increased [125I]sulpiride binding in the subthalamic nucleus of rats with nigrostriatal lesions

NeuroReport

Volumn 10, Issue 7, 1999, Pages 1501-1505

  Murer, M Gustavo ^c   Ferrario, Juan ^a   Delfino, Marina ^a   Dziewczapolski, Gustavo ^a   Gershanik, Oscar S ^a   Raisman Vozari, Rita ^b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c NONE

Author keywords

D2 class dopamine receptors; Levodopa; Parkinson's disease; Subthalamic nucleus

Indexed keywords

CARBIDOPA PLUS LEVODOPA; DOPAMINE; IODINE 125; SULPIRIDE; ANTIPARKINSON AGENT; DIAGNOSTIC AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; LEVODOPA; OXIDOPAMINE; RADIOACTIVE IODINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; FEMALE; IMMUNOHISTOCHEMISTRY; MESENCEPHALON; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; ORAL DRUG ADMINISTRATION; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS; ANIMAL; BRAIN MAPPING; DRUG EFFECT; METABOLISM; NERVE CELL; PHYSIOLOGY; RADIOASSAY; SUBSTANTIA NIGRA; THALAMUS NUCLEUS; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANTIPARKINSON AGENTS; BRAIN MAPPING; CORPUS STRIATUM; DOPAMINE; DOPAMINE ANTAGONISTS; FEMALE; IODINE RADIOISOTOPES; LEVODOPA; NEURONS; OXIDOPAMINE; RADIOLIGAND ASSAY; RATS; RATS, WISTAR; SUBSTANTIA NIGRA; SULPIRIDE; THALAMIC NUCLEI;

EID: 0033553266     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-199905140-00020     Document Type: Article

References (25)

1. 1. DeLong MR. Trends Neurosci 13, 281-285 (1990).
2. 2. Bergman H, Wichmann T and DeLong MR. Science 249, 1436-1438 (1990).
3. 3. Benazzouz A, Gross C, Féger J et al. Eur J Neurosci 5, 382-389 (1993).
4. 4. Limousin P, Pollak P, Benazzouz A et al. Lancet 354, 91-95 (1995).
5. 5. Gerten CR, Engber TM, Mathan LC et al. Science 250, 1429-1432 (1990).
6. 6. Hassani O-K, Mouroux M and Féger J. Neuroscience 72, 105-115 (1996).
7. 7. Brown LL, Makman MH, Woltson LI et al. Science 266, 1416-1418 (1979).
8. 8. Campbell GA, Eckhardt MJ and Weight FF. Brain Res 333, 261-270 (1985).
9. 9. Hassani O-K, Francois C, Yelnik J et al. Brain Res 749, 88-94 (1997).
10. 10. Savasta M, Dubois A and Scatton B. Brain Res 375, 291-301 (1986).
11. 11. Bouthenet M-L, Martres P, Sales N et al. Neuroscience 20, 117-155 (1987).
12. 12. Johnson AE, Coirini H, Kallstrom L et al. NeuroReport 5, 1836-1838 (1994).
13. 13. Kreiss DS, Anderson LA and Walters JR. Neurosci 72, 863-876 (1996).
14. 14. Parry TJ, Eberle-Wang K, Lucki I et al. Exp Neurol 128, 181-190 (1994).
15. 15. Mintz I, Hammond C and Féger J. Brain Res 375, 172-175 (1986).
16. 16. Kreiss DS, Mastropietro CW, Rawji SS et al. J Neurosci 17, 6807-6819 (1997).
17. 17. Paxinos G and Watson C. The Rat Brain in Stereotaxic Coordinates. New York: Academic Press, 1986.
18. 18. Murer MG, Dziewczapolski G, Menalled L et al. Ann Neurol 43, 561-575 (1998).
19. 19. Savasta M, Dubois A, Feuerstein C et al. Neurosci Lett 74, 180-186 (1987).
20. 20. Mengod G, Marinez-Mir MI, Vilaró MT et al. Proc Natl Acad Sci USA 86, 8560-8564 (1989).
21. 21. Mansour A, Meador-Woodruff JH, Bunzow JR et al. J Neurosci 10, 2587-2600 (1990).
22. 22. Weiner DM, Levey AI, Sunahara RK et al. Proc Natl Acad Sci USA 88, 1859-1863 (1991).
23. 23. Bouthenet M-L, Souil E, Martres M-P et al. Brain Res 564, 203-219 (1991).
24. 24. Yung KKL, Bolam JP, Smith AD et al. Neuroscience 65, 709-730 (1995).
25. 25. Vila M, Levy R, Herrero MT et al. J Neurosci 17, 765-776 (1997).